Aurinia Pharmaceuticals Inc. (AUPH) SEC Filings & Earnings Calls

Dependence on LUPKYNIS for revenue; pipeline risk.

“Single product revenue concentration; clinical development risks for aritinercept.”

Valuation allowance release increases tax expense

“The increase in the Company's income tax expense in 2026 over the same periods in 2025 is primarily the result of the Company's ability to utilize unrecognized deferred tax assets in 2025 to reduce the income tax expense.” · word for word

Integration risk and CVR-related contingent liabilities.

“CVR agreement with potential future payments; integration of Kezar's operations.”

Dependence on single product LUPKYNIS for revenue; pipeline risk for aritinercept.

“Revenue entirely from LUPKYNIS and Otsuka collaboration; aritinercept in early clinical development.”

Share repurchase reduces cash reserves; potential dilution from equity awards.

“Cash outflows from financing activities included $36.2M for share repurchase and $14.6M for tax withholding on equity awards.”

Management transition risk

“Effective March 23, 2026, the Company appointed Kevin Tang as Chief Executive Officer, Ryan Cole as Chief Operating Officer, and Michael Hearne as Chief Financial Officer.” · word for word

Valuation allowance release increases tax expense

“The change in the Company's effective tax rate is primarily due to the release of the Company's valuation allowance on deferred tax assets that the Company now expects to realize.” · word for word

Key person dependency on new CEO and management team

“Effective March 20, 2026, Mr. Greenleaf, Mr. Miller, Mr. Donley and Dr. Keenan ceased to serve as officers of Aurinia, and Mr. Greenleaf resigned from the Board of Directors of Aurinia effective March 21, 2026.” · word for word

Concentrated ownership by Tang Capital Management

“Tang Capital Management, LLC: 12,229,500 shares, 9.4%”

Closing conditions include minimum net cash of $50M and tender of >50% shares; no financing condition but execution risk remains.

“Closing conditions: Closing Net Cash >= $50.0M; at least one more share than 50% outstanding tendered.”

Complete management turnover; key executives from activist investor's firm; potential strategic shift or cost-cutting.

“CEO, COO, CFO all replaced by individuals from Tang Capital Management; prior CEO, COO, CMO, CFO all departed.”

CEO not taking compensation may indicate focus on shareholder value or potential sale.

“Kevin Tang elected to not receive any salary, bonuses, equity awards or other compensation.”

Generic competition risk from ANDA filings

“In February and March 2025, we received a paragraph IV notice of certification from each of Hikma Pharmaceuticals USA Inc., Lotus Pharmaceutical Co. Ltd., Galenicum Health S.L.U., Zydus Pharmaceuticals (USA) Inc., Teva Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Inc., DifGen Pharmaceuticals LLC and Sandoz Inc. advising that each company had submitted an” · word for word

Patent litigation and exclusivity expiration

“U.S. Patent No. 7,332,472: Our application for patent term extension ... was approved by the USPTO in December 2025, resulting in a term extending to October 2027. ... U.S. Patent Nos. 10,286,036 and 11,622,991 ... term extending to December 2037.” · word for word

Drug pricing and reimbursement pressure

“In the U.S. and internationally, sales of LUPKYNIS ... are dependent, in significant part, on the availability of adequate coverage and reimbursement. ... the Inflation Reduction Act of 2022 ... contains substantial drug pricing reforms, including the establishment of a drug price negotiation program ...” · word for word

Dependence on single product LUPKYNIS

“Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis.” · word for word

Clinical and regulatory risk for pipeline candidate aritinercept

“Aritinercept is a dual inhibitor of BAFF and APRIL for the potential treatment of autoimmune diseases. ... Aurinia has initiated a clinical study of aritinercept in one autoimmune disease and plans to initiate a clinical study in an additional autoimmune disease in the first half of 2026.”

Dependence on LUPKYNIS for revenue; pipeline risk for aritinercept.

“LUPKYNIS is the only marketed product; aritinercept is in early clinical development.”

Competition in lupus nephritis and autoimmune space.

“Potential new entrants and existing therapies.”

Regulatory and reimbursement risks for LUPKYNIS.

“FDA approval and payer coverage are critical.”

Dependence on LUPKYNIS for revenue; single product risk.

“LUPKYNIS is the only approved product generating significant revenue.”

Pipeline risk: aritinercept clinical trials may fail.

“Aritinercept advances toward clinical studies; clinical trial risks inherent.”

Revenue concentration on LUPKYNIS

“The Company's revenue is primarily derived from LUPKYNIS, a single product for lupus nephritis.”

Foreign exchange exposure on Monoplant lease

“The Monoplant lease is denominated in Swiss Francs, and foreign exchange remeasurement caused $9.3 million loss in 9M 2025.”